^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CDR404
i
Other names: CDR404
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CDR-Life
Drug class:
MAGE-A4 inhibitor
Related drugs:
13d
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors (clinicaltrials.gov)
P1, N=42, Not yet recruiting, CDR-Life AG
New P1 trial
|
CDR404
8ms
CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC) (SITC 2023)
Conclusions The high MAGE-A4 expression levels and the highly specific anti-cancer cell activity of CDR404 make it a highly attractive immunotherapy for development post-progression on ICI for patients with HLA-A*02:01+ SQ-NSCLC. A multi-tumor phase 1 trial of CDR404, including SQ-NSCLC, is expected to begin in 2024 with prospective patient selection for both HLA-A*02:01 and tumor MAGE-A4.
IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
|
HLA-A*02 • MAGEA4 expression
|
CDR404
10ms
Precise tumor & patient selection for CDR404: A bispecific & bivalent MAGE-A4 T cell engager (ESMO 2023)
Lack of response reported in another MAGE-A4 TCE trial (NCT03973333) where tumor screening in ovarian cancer was absent confirms that IHC selection will be essential for RNALOW tumors. In this regard, we have identified E7O1U as a highly specific MAGE-A4 antibody for precise IHC patient selection in the CDR404 trial.
Clinical
|
MAGEA4 (Melanoma antigen family A, 4)
|
CDR404
Share via
